Inlyta is a brand name of axitinib, approved by the FDA in the following formulation(s):
INLYTA (axitinib - tablet; oral)
Manufacturer: PFIZER
Approval date: January 27, 2012
Strength(s): 1MG, 5MG [RLD]
Has a generic version of Inlyta been approved?
No. There is currently no therapeutically equivalent version of Inlyta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inlyta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Inlyta.
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 27, 2017 - NEW CHEMICAL ENTITY
See also...
- Inlyta Consumer Information (Drugs.com)